{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:01Z","timestamp":1791357301358,"version":"4.3.1"},"reference-count":78,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\n<jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Preclinical Research<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n<\/jats:table-wrap><\/jats:p><jats:p>After the identification of the schizophrenia as an illness over a century ago, treatment of affected individuals included unspecific, mostly very robust methods including deep insulin coma and lobectomy\/leucotomy. The first relatively specific treatment of schizophrenia started about 60 years ago with the antipsychotic chlorpromazine. All currently approved antipsychotic drugs block dopamine receptors, indicating that manipulation of dopaminergic function is fundamental to a therapeutic response in psychosis. Despite refinements in their mechanism of action, the therapeutic effects of subsequent generations of antipsychotics are insufficient in claiming superiority over the first generation, with the possible exception of clozapine. Dopamine receptor blockade is necessary but not always sufficient for antipsychotic response and improvements have been reported with molecules acting on other receptors (glutamate, glycine, cannabidiol, estrogen), intracellular signaling proteins, or products of identified risk genes. Here, we review the current status of drugs under investigation. In addition, we emphasize that the development of the novel compounds to target the underlying cognitive dysfunction and negative symptom dimension of full blown schizophrenia, or attenuated psychosis syndrome and specific endophenotypes related to the increased risk of psychosis in the general population, alongside efforts to deconstruct the concept of schizophrenia(s), represent the best way to meet patient needs for better therapies and more favorable outcomes. Drug Dev Res 77 : 357\u2013367, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ddr.21337","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T02:19:30Z","timestamp":1473992370000},"page":"357-367","source":"Crossref","is-referenced-by-count":78,"title":["Improving Current Treatments for Schizophrenia"],"prefix":"10.1002","volume":"77","author":[{"given":"Nadja P.","family":"Maric","sequence":"first","affiliation":[{"name":"School of Medicine University of Belgrade Belgrade Serbia"},{"name":"Clinical Centre of Serbia Clinic for Psychiatry Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica J.","family":"Jovicic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia Clinic for Psychiatry Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mihaljevic","sequence":"additional","affiliation":[{"name":"Clinical Centre of Serbia Clinic for Psychiatry Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedo","family":"Miljevic","sequence":"additional","affiliation":[{"name":"School of Medicine University of Belgrade Belgrade Serbia"},{"name":"Institute of Mental Health Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14040435"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/23808993.2016.1140554"},{"key":"e_1_2_7_4_1","volume-title":"Dementia praecox or the group of schizophrenics","author":"Bleuler E.","year":"1950"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.11.009"},{"key":"e_1_2_7_6_1","first-page":"21","article-title":"Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr","volume":"33","author":"Braff DL","year":"2007","journal-title":"Bull"},{"key":"e_1_2_7_7_1","first-page":"410","article-title":"Metabolic issues in psychotic disorders with the focus on first\u2010episode patients: a review","volume":"25","author":"Britvic D","year":"2013","journal-title":"Psychiatr Danub"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.03.007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125313511487"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.11.031"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.04.023"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1174577"},{"key":"e_1_2_7_13_1","first-page":"398","article-title":"[N\u2010dimethylamino\u2010prophylchlorophenothiazine (4560 RP) therapy of confusional states]","volume":"110","author":"Delay J","year":"1952","journal-title":"Ann Med Psychol (Paris)"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.143420"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.09.018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.16"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt137"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2014.08.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21207"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.05.029"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.84"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.06.016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S42735"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150605111345"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2015.12.010"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.48.7.948"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.199"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788957528"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp006"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.66"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.05.012"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/eoid.12.4.655.23750"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.10.011"},{"key":"e_1_2_7_34_1","volume-title":"Dementia pr\u00e6cox and paraphrenia","author":"Kraepelin E.","year":"1971"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.03.008"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.33"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2010.01.014"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.02.014"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.07.015"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.2.145"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.08.026"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.01.011"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.7"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790361461"},{"key":"e_1_2_7_45_1","first-page":"5","article-title":"Dopamin, prolaktin i terapija psihoza (Dopamine, prolactin and treatment of psychoses)","volume":"47","author":"Maric N.","year":"2015","journal-title":"Psihijatrija danas"},{"key":"e_1_2_7_46_1","first-page":"88","article-title":"Weight gain associated with the treatment of psychotic disorders","volume":"3","author":"Maric N","year":"2007","journal-title":"Obes Metabo"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-004-0803-z"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01690.x"},{"key":"e_1_2_7_49_1","first-page":"1","article-title":"Treatment resistance\u201d enigma resolved by pharmacogenomics \u2013 a case study of clozapine therapy in schizophrenia","volume":"33","author":"Maric NP","year":"2015","journal-title":"J Med Biochem"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.2.134"},{"key":"e_1_2_7_51_1","unstructured":"McGuireP RobsonP CubalaWJ VasileD MorrisonP WrightS.2016. A double\u2010blind randomised placebo\u2010controlled parallel group trial of cannabidiol as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder. Abstracts 5th Biennial SIRS Conference Presentations. NPJ Schizophrenia 2: pO8.8 (Article number: 16010; doi:10.1038\/)"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182970490"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15l09920"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.47"},{"key":"e_1_2_7_55_1","unstructured":"NatesanS KapurS.2011. How antipsychotics work? In: Anthony S. David Shitij Kapur Peter McGuffin editors. Schizophrenia: the final frontier. A festschrift for Robin M. Murray. Psychology Press Hove New York. p 334."},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12202"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400856t"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.901"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000442935.15833.c5"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12060778"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.900"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1346"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13595"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1145194"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16549"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1065"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4122"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3704-1"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.133.2.197"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1201"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.08.020"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.05.006"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200033"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S34433"},{"key":"e_1_2_7_75_1","unstructured":"VanoverK DavisR O'gormanC SaillardJ WeingartM MatesS.2016. Positive phase 3 clinical trial of ITI\u2010007 for the treatment of schizophrenia: efficacy results from a randomized double\u2010blind placebo\u2010controlled trial. Abstract 5th Biennial SIRS Conference Presentations NPJ Schizophrenia 2: p O8.4 Article number: 16010; doi:10.1038\/"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv072"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.11"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00575-1"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs135"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21337","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:11:36Z","timestamp":1760371896000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/ddr.21337"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21337","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]}}}